Navigation Links
Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel

CEO Glenn A. Oclassen to Join Sleep Experts in Panel Hosted by Natixis


PT. RICHMOND, Calif., Oct. 1 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, President and Chief Executive Officer, will participate in a panel focused on middle-of-the-night (MOTN) insomnia at the Natixis Bleichroeder "Hidden Gems" Healthcare Conference.

Date: Monday, October 8, 2007

Panel Discussion: 3:45 p.m. ET

Company Presentation: 4:45 p.m. ET

Location: The Carlton Hotel at 88 Madison Avenue, New York, NY

Mr. Oclassen commented, "This is the first panel sponsored by the investment community to discuss the form of insomnia that is characterized by patients who awaken in the middle of the night and have difficulty returning to sleep. According to a recent survey conducted by the Stanford Sleep Epidemiology Research Center, it is estimated that up to 35% of Americans over the age of 18 suffer primarily from this and related forms of sleep disorder. Despite this large patient population, there is no pharmaceutical agent currently approved to treat this common sleep problem."

"Transcept is developing Intermezzo(TM) (zolpidem tartrate lozenge) for the treatment of such MOTN insomnia. In a recently completed Phase 3 sleep laboratory study, Intermezzo(TM) met the primary endpoint of decreasing sleep onset after a middle of the night awakening, without next day residual effects. I look forward to participating in this panel with these respected sleep experts and raising awareness of this aspect of insomnia."

The MOTN insomnia panel will be co-hosted by Corey Davis, Ph.D., and Jon LeCroy, M.D. of Natixis Bleichroeder. The panel of sleep experts will include Martin B. Scharf, PhD, Director, Center for Research in Sleep Disorders, Cincinnati, Ohio and Gary K. Zammit, Ph.D., Director of the Sleep Disorders Institute at St. Luke's/Roosevelt Hospital, NYC.

Dr. Davis commented, "The potential for the novel claim for MOTN dosing could reduce some of the lingering stigma attached to taking a sleep medication, and perhaps help accelerate growth in the prescription market to a level more consistent with the historical and emerging epidemiological studies that suggest a high prevalence of MOTN insomnia in the US population."

About Intermezzo(TM)

Intermezzo(TM) (zolpidem tartrate lozenge) is a low dose formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Formulated as a sublingual tablet that dissolves under the tongue, Intermezzo(TM) employs Transcept's Bimucoral(TM) technology to accelerate bioavailability. The company intends to file the Intermezzo(TM) NDA with the US Food and Drug Administration (FDA) in 2008.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product, Intermezzo(TM) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. TO-2060 is currently the subject of an initial proof of concept trial in the treatment of alcohol use disorder. For more information, please visit the Company's website at:

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Bruker Participates in Dutch Funded Super Microscope Project
4. Venture Investors early-stage fund grows to $115 million
5. Investor warns of angel-venture funding gap
6. Brazilian bio-industry should impress American investors
7. Investors raise $25 million for biodiesel plant
8. Bio-energy and cleantech grab attention of investors
9. Venture Investors to open Michigan office
10. Early-stage executives hear from investors
11. Commerce qualifies seven for investor tax credits
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... , ... November 24, 2015 , ... The Academy of ... Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person ... few years. Many AMA members have embraced this type of racing and several new ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) ... remaining 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) ... B Warrants") subject to the previously disclosed November ... 2015, which will result in the issuance of ... the issuance of such shares, there will be ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies ... being named to Deloitte's 2015 Technology Fast 500 list of the fastest growing ... a FDA-cleared, Class II medical device that speeds up orthodontic tooth movement by ...
Breaking Biology Technology:
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/26/2015)... PALO ALTO, Calif. and LAS ... – Nok Nok Labs , an innovator in ... FIDO Alliance , today announced the launch of its ... the first unified platform enabling organizations to use standards-based ... authentication. The Nok Nok S3 Authentication Suite is ideal ...
Breaking Biology News(10 mins):